Physician profile
Samuel Gray
NPI 1184088486
$2,285.50
in general payments reported to CMS, 2019-2025
24 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $181 · 2021: $120 · 2022: $321 · 2023: $198 · 2024: $268 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $647.39 | 2019 | |
| Smith+Nephew, INC. | $302.04 | 2020-2025 | Memofix Super Elastic Nitinol Staple System, Jet-X, Smart Tsf |
| Stryker Corporation | $218.52 | 2019 | |
| Organogenesis INC. | $172.46 | 2022-2023 | Puraply |
| Integra Lifesciences Corporation | $170.64 | 2019-2024 | Tcc-Ez |
| Kerecis Limited | $151.34 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Nevro Corp. | $81.13 | 2024 | Senza |
| Hydrofera LLC | $79.54 | 2023-2024 | Hydrofera Blue |
| Bioventus LLC | $57.88 | 2022 | |
| Triad Life Sciences INC. | $51.80 | 2022 | |
| Progenacare Global, LLC | $44.81 | 2023-2024 | |
| Kci USA, INC. | $43.76 | 2022-2023 | Activ.A.C., Promogran Prisma |
| Supreme Orthopedic Systems, LLC | $35.85 | 2025 | |
| Biowound Solutions, INC. | $30.39 | 2025 | Bio-Connekt |
| Abbott Laboratories | $27.42 | 2025 | Proclaim |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $25.03 | 2025 | Senza |
| Melinta Therapeutics, LLC | $24.60 | 2024 | Kimyrsa |
| Cashflow Solutions, LLC | $21.68 | 2025 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Medtronic, INC. | $18.78 | 2025 | Inceptiv |
| Paratek Pharmaceuticals, INC. | $18.27 | 2023 | Nuzyra |
| Solventum Corporation | $17.75 | 2024 | Promogran Prisma, Activ.A.C. |
| Misonix INC | $16.82 | 2021 | |
| Anika Therapeutics, INC. | $16.01 | 2025 | Tactoset |
| Paragon 28, INC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.